Follow us on Twitter
twitter icon@FreshPatents


Immunostimulator patents

      

This page is updated frequently with new Immunostimulator-related patent applications.




 Beta-glucan in combination with anti-cancer agents affecting the tumor microenvironment patent thumbnailBeta-glucan in combination with anti-cancer agents affecting the tumor microenvironment
The present invention relates to the combination of soluble β-glucan and anti-cancer agents that affect the tumor microenvironment. Soluble β-glucan promotes an immunostimulatory environment, which allows enhanced effectiveness of anti-cancer agents..
Biothera, Inc.


 Beta-glucan methods and compositions that affect the tumor microenvironment patent thumbnailBeta-glucan methods and compositions that affect the tumor microenvironment
This disclosure relates to the combination of soluble β-glucan and immune suppression-relieving agents that affect the tumor microenvironment. Soluble β-glucan promotes an immunostimulatory environment, which allows enhanced effectiveness of anti-angiogenics, checkpoint inhibitors including non-tumor targeting antibodies..
Biothera, Inc.


 Cell based assay to measure the t-cell stimulating capacity of anti-lag3 antibodies and other agents patent thumbnailCell based assay to measure the t-cell stimulating capacity of anti-lag3 antibodies and other agents
The present invention includes a human lag3 functional assay using a jurkat t-cell lymphoma cell line engineered to overexpress lag3 at an optimal level relative to cd3. The assay is useful, for example, for determining the immunostimulatory properties of lag3 modulators (e.g., inhibitors or activators).
Merck Sharp & Dohme Corp.


 Mature dendritic cell compositions and methods for culturing same patent thumbnailMature dendritic cell compositions and methods for culturing same
This invention provides methods to prepare and use immunostimulatory cells for enhancing an immune response. The invention provides a method for preparing mature dendritic cells (dcs), comprising the sequential steps of: (a) signaling isolated immature dendritic cells (idcs) with a first signal comprising an interferon gamma receptor (ifn-γr) agonist and/or a tumor necrosis factor alpha receptor (tnf-αr) agonist to produce signaled dendritic cells; and (b) signaling said signaled dendritic cells with a second transient signal comprising an effective amount of a cd40 agonist to produce ccr7+ mature dendritic cells.
Argos Therapeutics, Inc.


 Mature dendritic cell compositions and methods for culturing same patent thumbnailMature dendritic cell compositions and methods for culturing same
This invention provides methods to prepare and use immunostimulatory cells for enhancing an immune response. The invention provides a method for preparing mature dendritic cells (dcs), comprising the sequential steps of: (a) signaling isolated immature dendritic cells (idcs) with a first signal comprising an interferon gamma receptor (ifn-γr) agonist and/or a tumor necrosis factor alpha receptor (tnf-αr) agonist to produce signaled dendritic cells; and (b) signaling said signaled dendritic cells with a second transient signal comprising an effective amount of a cd40 agonist to produce ccr7+ mature dendritic cells.
Argos Therapeutics, Inc.


 Naturally-occurring cpg oligonucleotide compositions and therapeutic applications thereof patent thumbnailNaturally-occurring cpg oligonucleotide compositions and therapeutic applications thereof
The present invention relates to combination therapies for the treatment of a variety of disorders in mammals, including hepatic disorders and cancer. The combination of agents includes naturally-occurring (versus synthetic) oligonucleotides, particularly immunostimulatory oligodeoxynucleotides such as cpg odns, obtained from a natural source and one or more extracts from a gram positive bacteria, such as lactobacillus spp..
Labyrinth Holdings, Llc


 Immunostimulatory sequence oligonucleotides and methods of using the same patent thumbnailImmunostimulatory sequence oligonucleotides and methods of using the same
The invention provides immunomodulatory polynucleotides and methods for immunomodulation of individuals using the immunomodulatory polynucleotides.. .
Dynavax Technologies Corporation


 Uses of starch binding protein (sbp)-tagged immunostimulatory protein patent thumbnailUses of starch binding protein (sbp)-tagged immunostimulatory protein
The present invention relates to a method for preventing or treating virus and protozoa infection in a subject in need thereof comprising: orally administering to said subject an effective amount of a composition comprising a complex consisting of a starch binding protein (sbp)-tagged immunostimulatory protein and a sbp-binding matrix, wherein the immunostimulatory protein is from ganoderma species. The present invention also relates to a method for inducing interferon-gamma production in a subject in need thereof comprising: orally administering to said subject an effective amount of a composition comprising a complex consisting of a starch binding protein (sbp)-tagged immunostimulatory protein and a sbp-binding matrix, wherein the immunostimulatory protein is from ganoderma species.
Simpson Biotech Co., Ltd


 Immunostimulatory anti-ceacam1 antibody patent thumbnailImmunostimulatory anti-ceacam1 antibody
An anti-ceacam1 antibody includes at least one antibody heavy chain (vh) domain having antigen binding sites cdr1h, cdr2h and cdr3h, and at least one antibody light chain (vl) domain having antigen binding sites cdr1l, cdr2l and cdr3l. The antigen binding site cdr2h has a sequence homology of at least 80% to the amino acid sequence wintytgept (seq id no.
Universitaet Duisburg-essen


 Immunostimulatory compositions and methods of use thereof patent thumbnailImmunostimulatory compositions and methods of use thereof
Immunostimulatory compositions and methods of use are described to either enhance or diminish the immune stimulation effects of a honey or honey isolate by recognition of the presence of type ii arabinogalactan compounds and utilising this knowledge to tailor the concentration of such compounds thereby adjusting the immune stimulation effects.. .
Comvita New Zealand Ltd.


Immunostimulating agent

Wherein each symbol is as defined herein, have an immunostimulatory effect and are useful as immunostimulating agents, particularly as adjuvants, and for compositions containing such a compound, and for vaccines containing such a compound and an antigen.. .

Vaccine composition comprising complexed immunostimulatory nucleic acids and antigens packaged with disulfide-linked polyethyleneglycol/peptide conjugates

The present invention is directed to a composition or vaccine composition comprising a) an adjuvant component comprising or consisting of at least one immunostimulatory nucleic acid sequence, complexed with a complexing agent; b) an antigen, preferably a protein or peptide antigen and/or a nucleic acid sequence encoding said antigen; and c) a carrier molecule for combined packaging the adjuvant component and the antigen. The present invention is also directed to the first medical use of such a composition or vaccine composition and to the second medical use of such a composition or vaccine composition or components thereof for the treatment of diseases, such as infectious or cancer or tumour diseases as defined herein.
Curevac Ag

Screening assays for identifying differentiation-inducing agents and production of differentiated cells for cell therapy

The invention relates to assays for screening growth factors, adhesion molecules, immunostimulatory molecules, extracellular matrix components and other materials, alone or in combination, simultaneously or temporally, for the ability to induce directed differentiation of pluripotent and multipotent stem cells.. .
Advanced Cell Technology, Inc.

Composition for treating prostate cancer (pca)

The present invention relates to an active (immunostimulatory) composition comprising at least one rna preferably an mrna, encoding at least two (preferably different) antigens capable of eliciting an (adaptive) immune response in a mammal wherein the antigens are selected from the group consisting of psa (prostate-specific antigen), psma (prostate-specific membrane antigen), psca (prostate stem cell antigen), and steap (six transmembrane epithelial antigen of the prostate). The invention furthermore relates to a vaccine comprising an active (immunostimulatory) composition, and to the use of the active (immunostimulatory) composition (for the preparation of a vaccine) and/or of the vaccine for eliciting an (adaptive) immune response for the treatment of prostate cancer (pca), preferably of neoadjuvant and/or hormone-refractory prostate cancers, and diseases or disorders related thereto.
Curevac Ag

Lipid nanoparticle vaccine adjuvants and antigen delivery systems

The instant invention provides for novel lipid nanoparticle (lnp) formulations, containing cationic lipids, for use as vaccine adjuvants and/or as antigen delivery systems. It is an object of the instant invention to provide lnp formulations that demonstrate enhancements in humoral and cellular immunogenicity of vaccine antigens, particularly subunit vaccine antigens, when utilized alone or in combination with immunostimulatory agents (e.g.
Merck Sharp & Dohme Corp

Acinetobacter baumannii antigens and the uses thereof

The present invention relates to an isolated polypeptide antigen of acinetobacter baumannii, comprising at least an amino acid sequence selected from the group consisting of: (a) seq id nos: 1-5; (b) an amino acid sequence having at least 80% sequence identity to seq id nos: 1, 3, 4 or 5; (c) an amino acid sequence having at least 60% sequence identity to seq id no: 2; and (d) a fragment of the amino acid sequence according to (a) to (c); wherein the polypeptide having the amino acid sequence according to (b) to (d) has immunostimulatory activity. The universal polypeptide antigens of acinetobacter baumannii can be used in the universal vaccine preparation.
National Chung Hsing University

Cpg oligonucleotide analogs containing hydrophobic t analogs with enhanced immunostimulatory activity

The invention relates to oligonucleotides including at least one lipophilic substituted nucleotide analog and a pyrimidine-purine dinucleotide. The invention also relates to pharmaceutical compositions and methods of use thereof..
Coley Pharmaceutical Gmbh

Ezrin-derived peptides and pharmaceutical compositions thereof

The present invention relates to the field of medicine, specifically, to the field of chemical and pharmaceutical industry and concerns ezrin-derived peptides, in particular, a peptide comprising an amino acid sequence of general formula (i) x1 ekkrretvere x2x3, wherein each x represents a non-polar amino acid residue. The use of the peptides as immunostimulatory agents, and more specifically, for use in treating and preventing antiviral, antibacterial and antifungal infections, and treatment of diseases of the gi tract, in particular ulcerative disorders of the gi tract.
Nearmedic International Limited

Composition for treating lung cancer, particularly of non-small lung cancers (nsclc)

The present invention relates to an active (immunostimulatory) composition comprising at least one rna, preferably a mrna, encoding at least two (preferably different) antigens capable of eliciting an (adaptive) immune response in a mammal. The invention furthermore relates to a vaccine comprising said active (immunostimulatory) composition, and to the use of said active (immunostimulatory) composition (for the preparation of a vaccine) and/or of the vaccine for eliciting an (adaptive) immune response for the treatment of lung cancer, particularly of non-small cell lung cancers (nsclc), preferably selected from the three main sub-types squamous cell lung carcinoma, adenocarcinoma and large cell lung carcinoma, or of disorders related thereto.
Curevac Ag

Methods of t cell epitope profiling, making t cell compositions, and treating diseases

Disclosed herein is a method of detecting antigen specific t cells in a sample isolated from a subject and mapping immunostimulatory epitopes of the antigen. Such methods may be used in methods of making antigen specific t cell compositions, e.g., for the treatment of diseases such as cancer, infectious diseases and autoimmune disorders..
Opexa Therapeutics, Inc.

Composition for treating lung cancer, particularly of non-small lung cancers (nsclc)

The present invention relates to an active (immunostimulatory) composition comprising at least one rna, preferably a mrna, encoding at least two (preferably different) antigens capable of eliciting an (adaptive) immune response in a mammal. The invention furthermore relates to a vaccine comprising said active (immunostimulatory) composition, and to the use of said active (immunostimulatory) composition (for the preparation of a vaccine) and/or of the vaccine for eliciting an (adaptive) immune response for the treatment of lung cancer, particularly of non-small cell lung cancers (nsclc), preferably selected from the three main sub-types squamous cell lung carcinoma, adenocarcinoma and large cell lung carcinoma, or of disorders related thereto.
Curevac Ag

Immunogenic compound

The present application relates to an immunostimulatory compound comprising an immunostimulant portion and a peptide portion. The peptide portion is not a disease-associated immunogen.
Altimmune Uk Limited

Adjuvant compositions

Adjuvant compositions comprising type 1 interferon inducers, such as double-stranded rna, in combination with antigen delivery systems and/or immunostimulatory molecules, such as immunostimulatory nucleic acid sequences, for enhancing the immune response of a coadministered antigen, are described.. .
Glaxosmithkline Biologicals Sa

Composition for treating prostate cancer (pca)

The present invention relates to an active (immunostimulatory) composition comprising at least one rna, preferably an mrna, encoding at least two (preferably different) antigens capable of eliciting an (adaptive) immune response in a mammal wherein the antigens are selected from the group consisting of psa (prostate-specific antigen), psma (prostate-specific membrane antigen), psca (prostate stem cell antigen), and steap (six transmembrane epithelial antigen of the prostate). The invention furthermore relates to a vaccine comprising an active (immunostimulatory) composition, and to the use of the active (immunostimulatory) composition (for the preparation of a vaccine) and/or of the vaccine for eliciting an (adaptive) immune response for the treatment of prostate cancer (pca), preferably of neoadjuvant and/or hormone-refractory prostate cancers, and diseases or disorders related thereto.
Curevac Ag

Enzymes and methods for cleaving n-glycans from glycoproteins

Provided herein are deglycosylating enzymes that remove a broad range of n-glycans from n-glycosylated proteins. Further provided are methods of recombinantly producing and expressing the deglycosylating enzymes.
The Regents Of The University Of California

Novel influenza virus vector for virotherapy

The present invention provides a recombinant influenza virus vector comprising an ns gene encoding a truncated ns1 protein of at least 73 and up to 122 amino acids of the n-terminus of the respective wild type ns 1 protein, wherein said vector replicates in ifn-sensitive tumor cells and does not replicate in normal, non-tumor cells, and expresses a heterologous immunostimulatory polypetide. The invention further provides a pharmaceutical composition containing said influenza virus vector, its use for the treatment of cancer patients and methods for producing said influenza virus vaccine..

Method of producing a substance with antimicrobial, antiviral, and immunostimulatory activities, a substance and a composition

A method of producing a substance with antimicrobial, antiviral, and immunostimulatory activities, particularly towards dendritic cells is proposed, provides for using the chopped potato sprouts as plant raw materials are extracted with water, then the aqueous extract is centrifuged, a salt agent is added, and the obtained saline solution is then concentrated using ultrafiltration through a 300-kd filter, then the solution is frozen for 24 hours, thawed, and filtered, and the pellet thus obtained is removed, and the raw peptidoglycan is precipitated from the solution by using an acidic salt agent and is further re-solubilized with alkali, then the alkaline solution is dialyzed against distilled water on a 12 kd filter, and the peptidoglycan having a molecular weight of 500 kd to 17000 kd is purified from the resulting solution using gel permeation chromatography.. .
Silezia Group Pte. Ltd

Modified rna with decreased immunostimulatory properties

The present invention provides a method for providing modified mrnas of reduced immunogenicity and/or immunostimulatory capacity for use in protein replacement therapy. The invention further provides modified mrnas and pharmaceutical compositions comprising the modified mrnas according to the invention for use in protein replacement therapy..
Curevac Ag

Agents and methods based on the use of the eda domain of fibronectin

This invention relates to the use of a polypeptide in the production of an immunostimulatory agent, said polypeptide comprising a sequence corresponding to the eda domain of fibronectin, a fragment of the eda domain which can bind to tlr4 or a variant of said eda domain or a fragment which can bind to tlr4 and which has a homology of more than 70% with any form or natural fragment of the eda domain. The invention also relates to the production methods and applications of said agent..
Proyecto De Biomedicina Cima, S.l.

Adsorption of immunopotentiators to insoluble metal salts

Immunopotentiators can be adsorbed to insoluble metal salts, such as aluminium salts, to modify their pharmacokinetics, pharmacodynamics, intramuscular retention time, and/or immunostimulatory effect. Immunopotentiators are modified to introduce a moiety, such as a phosphonate group, which can mediate adsorption.
Glaxosmithkline Biologicals Sa

Spherical nucleic acid-based constructs as immunostimulatory agents for prophylactic and therapeutic use

Aspects of the invention relate to spherical nucleic acid-based constructs and related methods and compositions thereof. The compositions of the invention are useful for activating agonists of nucleic acid interacting complexes, such as tlrs, stimulating an immune response, and treating diseases such as infectious disease, cancer, allergies, allergic diseases, and autoimmune disease.

Cpg-oligodeoxynucleotide, immunogenic composition comprising the same, and methods for preparing the composition and stimulating immune response thereby

Cpg-oligodeoxynucleotides (cpg-odn), as potent immune stimuli developed for using as adjuvant in different species, are disclosed herein. Tlr9 is the cellular receptor for cpg-odn, and current developed cpg-odn has low activity to rabbit tlr9.
National Health Research Institutes

Bifunctional protein anchors

The disclosure relates to the areas of immunology and vaccine delivery. More specifically, it relates to a bacterial vaccine delivery technology with built-in immunostimulatory properties which allow the immobilization of any antigen of interest, without prior antigen modification.
Applied Nanosystems B.v.

Pharmaceutical compositions comprising a gpg oligodeoxynucleotide and cyclic di-gmp

The present invention relates to pharmaceutical compositions comprising an immunostimulatory amount of at least two immunopotentiators, wherein a first immunopotentiator is a non-methylated cytidyl guanosyl oligodeoxynucleotide (cpg odn) and a second immunopotentiator is 3′,5′-cyclic diguanylic acid (c-di-gmp), and a pharmaceutically acceptable carrier. The invention also relates to the use of such pharmaceutical compositions for the induction of an immune response against tumor-specific antigens.
Intervet Inc.

Immunostimulatory combinations

The present invention provides immunostimulatory combinations. Generally, the immunostimulatory combinations include a tlr agonist and a tnf/r agonist.
Trustees Of Dartmouth College

Silencing of polo-like kinase expression using interfering rna

The present invention provides compositions comprising interfering rna (e.g., sirna, airna, mirna) that target polo-like kinase 1 (plk-1) expression and methods of using such compositions to silence plk-1 expression. More particularly, the present invention provides unmodified and chemically modified interfering rna molecules which silence plk-1 expression and methods of use thereof.
Protiva Biotherapeutics, Inc.

Immunostimulatory compositions and methods of use thereof

Lipid conjugates for enhanced delivery of cargo to the lymph nodes are disclosed. The lipid conjugates typically include three domains: a lipophilic domain that binds to albumin, a polar block domain, and a cargo such as a molecular adjuvant or immunostimulatory compound (such as an oligonucleotide) or antigenic peptide.
Massachusetts Institute Of Technology

Immunostimulatory compound

An immunostimulatory compound is disclosed.. .
Eisai R&d Management Co., Ltd.

Compositions and methods of enhancing immune responses to enteric pathogens

Vaccine vectors capable of eliciting an immune response to enteric bacteria and methods of using the same are provided. The vaccine vectors include a polynucleotide encoding a pal polypeptide.
The Texas A&m University System

2-fluoro-modified rnas as immunostimulators

Methods of inhibiting the growth of cells or inducing cell death by contacting the cells with or introducing into the cells a composition including a 5′ triphosphate, 2′ fluoro-modified pyrimidine non-linear single stranded rna at least 17 nucleotides long with a least 3 base pairings or a 5′ triphosphate, 2′ fluoro-modified double stranded rna at least 17 base pairs long in an amount effective to inhibit cell growth, induce cell death or induce cytokine production by the cells. The methods also include administration of the compositions to a subject.
Duke University

Immunostimulatory combinations and use thereof

Immunostimulatory combination are provided comprising: (i) a tlr agonist, (ii) a cd40 agonist, and (iii) an antigen, wherein said antigen consists of one or more antigenic peptides which range in size from 6-14 amino acids in length, wherein these moieties are each present in an amount that, in combination with the other, is effective to increase a subject's immune response to an antigen. The use of such short peptides unexpectedly enhances cd8+ t cell immunity..

Vectors and methods for genetic immunization

Improved dna vaccine plasmids are disclosed that contain novel immunostimulatory rna compositions. The improved plasmids eliminate all extraneous sequences, incorporate a novel antibiotic free short rna based selectable marker, increase eukaryotic expression using a novel chimeric promoter, improve yield and stability during bacterial production, and improve immunostimulation.
Nature Technology Corporation

Synthetic conjugate of cpg dna and t-help/ctl peptide

Highly effective vaccine compositions are constructed according to the methods of this invention. The methods are amenable to use with any peptidic antigen sequence and involve covalent attachment of an immunostimulatory nucleotide sequence to an antigenic peptide sequence.
City Of Hope

Vectors and methods for genetic immunization

Improved dna vaccine plasmids are disclosed that contain novel immunostimulatory rna compositions. The improved plasmids eliminate all extraneous sequences, incorporate a novel antibiotic free short rna based selectable marker, increase eukaryotic expression using a novel chimeric promoter, improve yield and stability during bacterial production, and improve immunostimulation.
Nature Technology Corporation

Methods and compositions for modulating an immune response with immunogenic oligonucleotides

This document relates to compositions and methods for modulating an immune response. For example, compositions of immunostimulatory cpg oligonucleotides derived from retroviral genomes are provided..
Creation One Formulators, Llc

Methods of determining cell mediated response

The invention relates to the use of one of more biomarkers, such as granzyme b, to determine an immune response, such as a cell-mediated immune response, of a subject to an immunostimulatory composition. The invention also relates to methods of treating a subject determined to develop a poor immune response to an immunostimulatory composition.
Advanced Medical Research Institute Of Canada

Crushed bacterial body and compositions thereof

A crushed bacterial cells can be obtained by culturing a gram-negative bacterium and physically crushing a body of the gram-negative bacterium, comprises all components including immunostimulatory components in the bacterial cells, and comprises lpss having molecular weights of 20,000 or less as active ingredients. The crushed bacterial cells is effective as a health food, drug, skin-care product, bath agent, feedstuff for protecting crustaceans, shellfish, fish, poultry, farm animals and pet animals from infections, and a feed additive for growth promotion, and can provide an innate immunostimulatory substance derived from a gram-negative bacterial cells having infection-preventing effects and growth promoting effects, an inexpensive and practical microbial crushed bacterial cells, and a composition thereof..
Soma, Gen-ichiro

High-affinity peptide-based anticancer vaccination to overcome tumor resistance to immunostimulatory antibodies and to identify tcrs that can be used successfully in adoptive t cell therapy

The invention provides a methodology to use cancer vaccination to overcome tumor resistance to immunostimulatory antibodies. Our cancer vaccination approach relies on targeting mutant tumor-specific peptides that have high affinity for the major histocompatibility complex.

Optimization of antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof

The present invention provides isolated monoclonal antibodies that specifically bind lag-3, and have optimized functional properties compared to previously described anti-lag-3 antibodies, such as antibody 25f7 (us 2011/0150892 a1). These properties include reduced deamidation sites, while still retaining high affinity binding to human lag-3, and physical (i.e., thermal and chemical) stability.
Bristol-myers Squibb Company

Hmgb1-derived peptides enhance immune response to antigens

The invention also provides an immunostimulatory peptide containing the amino acid sequence dpnapkrppsafflx1x2x3x4 or derivatives thereof. In one embodiment, when x1 is alanine (a), glycine (g), or valine (v) then x2 is c, x3 is s and x4 is e; wherein when x2 is alanine (a), glycine (g), or valine (v) then x1 is f, x3 is s and x4 is e; wherein when x3 is alanine (a), glycine (g), or valine (v) then x1 is f, x2 is c and x4 is e; or wherein when x4 is alanine (a), glycine (g), or valine (v) then x1 is f, x2 is c and x3 is s..

Mertk-specific pyrimidine compounds

The present invention includes pyrimidine compounds that selectively inhibit mer tyrosine kinase (mertk) activity and/or tyro3 tyrosine kinase activity, and use of these pyrimidine compounds as anti-cancer agents, immunostimulatory and immunomodulatory agents, anti-platelet agents, anti-infective agents, and as adjunctive agents in combination with chemotherapeutic, radiation or other standard of care for neoplasms.. .

Mertk-specific pyrrolopyrimidine compounds

The present invention includes pyrrolopyrimidine compounds that selectively inhibit mer tyrosine kinase (mertk) activity and/or tyro3 tyrosine kinase activity, and use of these pyrrolopyrimidine compounds as anti-cancer agents, immunostimulatory and immunomodulatory agents, anti-platelet agents, anti-infective agents, and as adjunctive agents in combination with chemotherapeutic, radiation or other standard of care for neoplasms.. .

Mertk-specific pyrazolopyrimidine compounds

The present invention includes pyrazolopyrimidine compounds of formula i that selectively inhibit mer tyrosine kinase (mertk) activity and/or tyro3 tyrosine kinase activity, and use of these pyrazolopyrimidine compounds as anti-cancer agents, immunostimulatory and immunomodulatory agents, anti-platelet agents, anti-infective agents, and as adjunctive agents in combination with chemotherapeutic, radiation or other standard of care for neoplasms.. .



Immunostimulator topics:
  • Immunostimulator
  • Stimulator
  • Immune Response
  • Immunomodulator
  • Nucleic Acid
  • Prophylaxis
  • Monoclonal Antibody
  • Specificity
  • Compatibility
  • Monoclonal
  • Therapeutics
  • Major Histocompatibility Complex
  • Histocompatibility
  • Antibodies
  • Immunotherapy


  • Follow us on Twitter
    twitter icon@FreshPatents

    ###

    This listing is a sample listing of patent applications related to Immunostimulator for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Immunostimulator with additional patents listed. Browse our RSS directory or Search for other possible listings.


    0.4484

    file did exist - 2753

    1 - 1 - 53